Dr Reddy's Laboratories Looking back at the company’s recent challenges, we see a very tough 2009, largely due to the Betapharm acquisition and the subsequent changes in German regulations. How do you explain the situation there and what measures did you take to turn the situation around? Germany, and in particular the Betapharm…
Cegedim Mexico From your perspective in healthcare consultancy at CEGEDIM, what do you think have been the most impactful changes in the Mexican pharmaceutical and healthcare sector over the last few years? One of the most important issues that changed in the Mexican pharmaceutical industry is the growth of generics, and this…
PharmaLegacy Could you give us some personal background and tell us why you choose to come to the CRO side after a successful career at a multinational? A lot of people ask why I chose to make this transition after being at a pretty good position at Procter & Gamble, with…
Finnegan Finnegan is a leader and expert on the topic of intellectual property and it entered Asia in the late 1980s with an office in Tokyo yet China only very recently. Can you provide what the initial impetus was to enter China as well as the operations here since 2008? As…
Amega Biotech What was the vision behind the creation of the umbrella organisation Amega Biotech in 2005? What led you to consider setting up an organisation with this structure, and offering these services in particular? When we started Amega, the idea was to exploit this argentine know-how that had not been touched…
Cegedim Hungary Talking to Cegedim means talking to one of the experts in local market knowledge. Can you tell our readers from your point of view what really distinguishes Hungary from other pharmaceutical markets in the region? I think key particularities are the many legal constraints. In July 2011, the law changed…
EGIS Romania You have been general manager of this affiliate for three years after a previous tenure as general manager of Leo Pharma here and in Bulgaria. The end of 2008 through 2010 were certainly not the easiest years for pharmaceutical companies. What was the business environment like when you first came…
Cegedim Strategic Data Malaysia Nowadays we can talk of an abundance of information coming from companies like Frost& Sullivan, IMS and even consultancies who are producing their own data. As a leader in market research how can CSD find a space within this picture and what strategies does it employ to stay ahead of…
Office for the Strategic Coordination of Health Research (OSCHR) It are exciting times for the UK, with the public healthcare system undergoing so many changes. The Office of Life Sciences (OLS) and the Therapeutic Capability Clusters are just some examples of the new way forward. According to you, what are the factors that drove Government to pursue such drastic…
Promega Netherlands Promega is a truly global company with a vast international presence. What would you say is the strategic importance that the Benelux affiliate has assumed within Promega’s global network? Promega Benelux is actually the first branch office that was established outside of the US, so the company’s experience in bringing…
Cegedim Deutschland GmbH You joined Cegedim in summer 2006 eleven months before its merger with Dendrite in 2007 that created the world leader in pharmaceutical CRM. How would you describe the integration process of both companies and what were the main synergies between Cegedim and Dendrite in the German context? Germany offered a…
Cegedim Dendrite South Korea You have been working in the CRM industry, particularly with pharmaceutical companies, for more then 10 years. Could you briefly introduce to our readers how the CRM industry has evolved in South Korea throughout this period? I understand that ETMS (Electronic Territory Management System) was introduced to Korea in late…
See our Cookie Privacy Policy Here
